阿司匹林、其他非甾体抗炎药及对乙酰氨基酚的使用与子宫内膜癌风险:子宫内膜癌流行病学联盟研究
该研究汇总7项队列和5项病例对照研究的个体数据(7120例子宫内膜癌患者、16069例对照),发现超重和肥胖女性中每周至少使用阿司匹林或非阿司匹林非甾体抗炎药与子宫内膜癌风险降低约15%相关,正常体重女性中无关联,对乙酰氨基酚无明确关联。
要点
- 超重女性每周至少使用阿司匹林者子宫内膜癌风险降低(OR=0.86,95%CI 0.76-0.98)。
- 肥胖女性每周至少使用非阿司匹林非甾体抗炎药与风险降低相关(OR=0.84,95%CI 0.74-0.96)。
- 正常体重女性中阿司匹林和非甾体抗炎药均无关联(异质性P=0.04和P=0.003)。
核心结论
- 汇总分析进一步提供证据表明,超重和肥胖女性使用标准剂量阿司匹林或其他非甾体抗炎药可能降低子宫内膜癌风险。
研究设计与样本
- 汇总子宫内膜癌流行病学联盟中7项队列研究和5项病例对照研究的个体水平数据,共纳入7120例子宫内膜癌患者和16069例对照。
主要发现
- 超重女性每周至少使用阿司匹林者子宫内膜癌风险降低(OR=0.86,95%CI 0.76-0.98),肥胖女性亦降低(OR=0.86,95%CI 0.76-0.97)。
- 超重女性每周至少使用非阿司匹林非甾体抗炎药者风险降低(OR=0.87,95%CI 0.76-1.00),肥胖女性亦降低(OR=0.84,95%CI 0.74-0.96)。
- 正常体重女性(体重指数<25 kg/m2)中未见关联(阿司匹林异质性P=0.04,非甾体抗炎药异质性P=0.003)。
- 超重和肥胖女性中,阿司匹林每周使用2-6次者(OR=0.81,95%CI 0.68-0.96)比每日使用者(OR=0.91,95%CI 0.80-1.03)的负向关联更强。
- 对乙酰氨基酚使用与子宫内膜癌风险无明确关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regular use of aspirin has been associated with a reduced risk of cancer at several sites but the data for endometrial cancer are conflicting. Evidence regarding use of other analgesics is limited. PATIENTS AND METHODS: We pooled individual-level data from seven cohort and five case-control studies participating in the Epidemiology of Endometrial Cancer Consortium including 7120 women with endometrial cancer and 16 069 controls. For overall analyses, study-specific odds ratios (ORs) and 95% confidence intervals (CI) were estimated using logistic regression and combined using random-effects meta-analysis; for stratified analyses, we used mixed-effects logistic regression with study as a random effect. RESULTS: At least weekly use of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an approximately 15% reduced risk of endometrial cancer among both overweight and obese women (OR = 0.86 [95% CI 0.76-0.98] and 0.86 [95% CI 0.76-0.97], respectively, for aspirin; 0.87 [95% CI 0.76-1.00] and 0.84 [0.74-0.96], respectively, for non-aspirin NSAIDs). There was no association among women of normal weight (body mass index < 25 kg/m2, Pheterogeneity = 0.04 for aspirin, Pheterogeneity = 0.003 for NSAIDs). Among overweight and obese women, the inverse association with aspirin was stronger for use 2-6 times/week (OR = 0.81, 95% CI 0.68-0.96) than for daily use (0.91, 0.80-1.03), possibly because a high proportion of daily users use low-dose formulations. There was no clear association with use of acetaminophen. CONCLUSION: Our pooled analysis provides further evidence that use of standard-dose aspirin or other NSAIDs may reduce risk of endometrial cancer among overweight and obese women.
引用
- Webb PM, Na R, Weiderpass E, et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium. Ann Oncol. 2019. PMID: 30566587. doi:10.1093/annonc/mdy541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。